
1 Drug Supply Chain
2 Security Act
3 Implementation:
4 Identification of
5 Suspect Product and
6 Notification
7 Guidance for Industry

8
9
10
11
12
13
14
15 U.S. Department of Health and Human Services
16 Food and Drug Administration
17 Center for Drug Evaluation and Research (CDER)
18 Center for Biologics Evaluation and Research (CBER)
19 Office of Regulatory Affairs (ORA)

20
21 XXXX 2015
22 Procedural

23 Drug Supply Chain Security
24 Act Implementation:
25 Identification of Suspect
26 Product and Notification
27 Guidance for Industry

28
29
30
31
32 *Additional copies are available from:*
33 *Office of Communications*
34 *Division of Drug Information, WO51, Room 2201*
35 *Center for Drug Evaluation and Research*
36 *Food and Drug Administration*
37 *10903 New Hampshire Ave., Silver Spring, MD 20993*
38 *Phone: 301-796-3400; Fax: 301-847-8714*
39 *druginfo@fda.hhs.gov*

40 <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

41
42 *and/or*

43
44 *Office of Communication, Outreach and Development*
45 *Center for Biologics Evaluation and Research*
46 *Food and Drug Administration*
47 *10903 New Hampshire Ave., WO 71, Room 3128*
48 *Silver Spring, MD 20993*
49 *Phone: 800-835-4709 or 240-402-7800*
50 ocod@fda.hhs.gov

51 <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>

52
53
54 **U.S. Department of Health and Human Services**
55 **Food and Drug Administration**
56 **Center for Drug Evaluation and Research (CDER)**
57 **Center for Biologics Evaluation and Research (CBER)**
58 **Office of Regulatory Affairs (ORA)**

59
60 **XXXX 2015**
61 **Procedural**

TABLE OF CONTENTS

62
63
64
65 **I. INTRODUCTION.....1**
66 **II. BACKGROUND.....2**
67 **A. Drug Supply Chain Security Act.....2**
68 **B. Scope of This Guidance.....3**
69 **III. IDENTIFICATION OF SUSPECT PRODUCT AND, FOR MANUFACTURERS,**
70 **PRODUCT WITH A HIGH RISK OF ILLEGITIMACY.....3**
71 **A. Specific Scenarios That Could Significantly Increase the Risk of a Suspect Product Entering**
72 **the Pharmaceutical Distribution Chain.....4**
73 *1. Trading Partners and Product Sourcing.....4*
74 *2. Supply, Demand, History, and Value of the Product.....5*
75 *3. Appearance of the Product.....6*
76 **B. Recommendations on How Trading Partners Might Identify Suspect Product and**
77 **Determine Whether the Product Is a Suspect Product as Soon as Practicable.....6**
78 **C. For Manufacturers: High Risk of Illegitimacy Notifications.....8**
79 *1. High Risk of Illegitimacy Notification for Products that the Manufacturer Has Reason to Believe*
80 *Are in an Immediate Trading Partner’s Possession.....9*
81 *2. Specific High Risks That Could Increase the Likelihood of an Illegitimate Product Entering the*
82 *U.S. Pharmaceutical Distribution Supply Chain.....10*
83 *3. Other High Risks as Determined by FDA: High Risk of Illegitimacy Notification Where a*
84 *Manufacturer has Reason to Believe the Product has Entered the Pharmaceutical Distribution*
85 *Supply Chain.....10*
86 **IV. NOTIFICATION OF ILLEGITIMATE PRODUCT AND PRODUCTS WITH A**
87 **HIGH RISK OF ILLEGITIMACY.....11**
88 **A. Notification to FDA.....11**
89 *1. The following process should be used to notify FDA of illegitimate products:.....12*
90 *2. The following process should be used by manufacturers to notify FDA of a product with a high*
91 *risk of illegitimacy:.....12*
92 **B. Termination of Notification in Consultation With FDA.....13**
93 **ATTACHMENT A: FORM FDA 3911.....16**
94

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Guidance for Industry¹

Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification

This guidance represents the Food and Drug Administration's (FDA's) current thinking on this topic. With the exception of section IV.B,² it does not create or confer any rights for or on any person and does not operate to bind the FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance is intended to aid trading partners³ (manufacturers, repackagers, wholesale distributors, and dispensers) in identifying a suspect product and terminating notifications. As of January 1, 2015, a trading partner that determines a product in its possession or control is an illegitimate product must notify the Food and Drug Administration (FDA or Agency) and certain immediate trading partners under section 582 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee), as added by the Drug Supply Chain Security Act (DSCSA). Manufacturers are additionally required under section 582 to notify FDA and certain immediate trading partners after the manufacturer determines or is notified by FDA or a trading partner that there is a high risk that a product is illegitimate. This guidance identifies specific scenarios that could significantly increase the risk of a suspect product entering the pharmaceutical distribution supply chain; provides recommendations on how trading partners can identify a product and determine whether a product is a suspect product as soon as practicable; and sets forth the process by which trading partners should notify FDA of illegitimate product or products with a high risk of illegitimacy, and how they must terminate the notifications, in consultation with FDA.

This guidance does not address all provisions of the DSCSA related to suspect and illegitimate products. As FDA works to implement other provisions of the DSCSA, the Agency intends to

¹ This guidance has been prepared by the Office of Compliance in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) and the Office of Regulatory Affairs (ORA) at the Food and Drug Administration.

² Congress gave FDA authority to implement through binding guidance the process for terminating notifications of illegitimate product in consultation with FDA. Thus, the discussion of the termination process in section IV has binding effect.

³ For this guidance, *trading partner* is defined as described in section 581(23)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 30eee(23)(A)), and refers to a manufacturer, repackager, wholesale distributor, or dispenser. For purposes of this guidance, *trading partner* does not refer to a third-party logistics provider (3PL) as defined at section 581(23)(B) of the FD&C Act (21 U.S.C. 360eee(23)(B)), though FDA encourages 3PLs to follow the recommendations in this guidance to the extent relevant to the 3PL's operations.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

129 issue additional information to support efforts to develop standards, issue guidance and
130 regulations, establish pilot programs, and conduct public meetings.

131

132 FDA’s guidance documents, in general, do not establish legally enforceable responsibilities.
133 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
134 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
135 the word *should* in Agency guidances means that something is suggested or recommended, but
136 not required. Insofar as section IV.B of this guidance sets forth the process by which trading
137 partners must terminate notifications of illegitimate product and products with a high risk of
138 illegitimacy in consultation with FDA, it has binding effect.⁴

139

140 **II. BACKGROUND**

141

142 **A. Drug Supply Chain Security Act**

143

144 On November 27, 2013, the DSCSA (Title II of Public Law 113-54) was signed into law.
145 Section 203 of the DSCSA added new section 582(h)(2) to the FD&C Act, which requires FDA
146 to issue guidance to aid trading partners in identifying a suspect product and terminating
147 notifications. *Suspect product* is defined in section 581(21) of the FD&C Act as a product for
148 which there is reason to believe it (A) is potentially counterfeit, diverted, or stolen; (B) is
149 potentially intentionally adulterated such that the product would result in serious adverse health
150 consequences or death to humans; (C) is potentially the subject of a fraudulent transaction; or
151 (D) appears otherwise unfit for distribution such that the product would result in serious adverse
152 health consequences or death to humans. Section 582 of the FD&C Act requires trading
153 partners, upon determining that a product in their possession or control is a suspect product, to
154 quarantine the product while they promptly conduct an investigation to determine whether the
155 product is an illegitimate product. *Illegitimate product* is defined in section 581(8) of the FD&C
156 Act as a product for which credible evidence shows that it is (A) counterfeit, diverted, or stolen;
157 (B) intentionally adulterated such that the product would result in serious adverse health
158 consequences or death to humans; (C) is the subject of a fraudulent transaction; or (D) appears
159 otherwise unfit for distribution such that the product would be reasonably likely to result in
160 serious adverse health consequences or death to humans.⁵

161

162 Section 582 of the FD&C Act requires trading partners, upon determining that a product in their
163 possession or control is illegitimate, to notify FDA and all immediate trading partners (that they
164 have reason to believe may have received the illegitimate product) not later than 24 hours after
165 making the determination. Manufacturers are additionally required under section 582(b)(4)(B)
166 (ii)(II) to notify FDA and immediate trading partners (that the manufacturer has reason to believe
167 may possess a product manufactured by or purported to be manufactured by the manufacturer)

12 ⁴ Section 582 of the FD&C Act gives FDA authority to issue binding guidance on the process for terminating
13 notifications of illegitimate product. Specifically, section 582(h)(2)(A) states that FDA “shall issue a guidance
14 document to aid trading partners in the identification of a suspect product and notification termination. Such
15 guidance document shall . . . set forth the process by which manufacturers, repackagers, wholesale distributors, and
16 dispensers shall terminate notifications in consultation with the Secretary regarding illegitimate product . . .”

17 ⁵ For additional definitions applicable to this guidance, please refer to section 581 of the FD&C Act.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

168 not later than 24 hours after the manufacturer determines or is notified by FDA or a trading
169 partner that there is a high risk that the product is illegitimate.

170
171 The DSCSA outlines critical steps to build an electronic, interoperable system over the next 10
172 years that will identify and trace certain prescription drugs as they are distributed within the
173 United States (U.S.). For many years, FDA has been engaged in efforts to improve the security
174 of the drug supply chain to protect U.S. patients from unsafe, ineffective, and poor quality drugs.
175 Since the formation of the first FDA Counterfeit Drug Task Force in 2003, FDA has strongly
176 advocated for a multilayered approach to securing the supply chain. A key component of that
177 approach has been to encourage heightened vigilance and awareness among supply chain
178 partners. The electronic, interoperable system that will be established under the DSCSA will
179 enhance FDA's ability to help protect U.S. consumers by improving detection and removal of
180 potentially dangerous drugs from the drug supply chain.

181

B. Scope of This Guidance

182
183

184 Pursuant to section 582(h)(2) of the FD&C Act, this guidance identifies specific scenarios that
185 could significantly increase the risk of a suspect product entering the pharmaceutical distribution
186 chain; provides recommendations on how trading partners can identify a product and determine
187 whether a product is a suspect product as soon as practicable; describes when manufacturers
188 should notify FDA of a high risk that a product is illegitimate; and sets forth the process by
189 which trading partners must terminate notifications in consultation with FDA regarding
190 illegitimate product under section 582(b)(4)(B)(iv), (c)(4)(B)(iv), (d)(4)(B)(iv), and (e)(4)(B)(iv)
191 of the FD&C Act and the process for terminating notifications in consultation with FDA
192 regarding products with a high risk of illegitimacy under section 582(b)(4)(B)(iv). This guidance
193 also addresses how trading partners should notify FDA when they determine that a product in
194 their possession or control is an illegitimate product under section 582(b)(4)(B)(ii)(I), (c)(4)(B)
195 (ii), (d)(4)(B)(ii), and (e)(4)(B)(ii) of the FD&C Act, and how manufacturers should notify FDA
196 regarding products with a high risk of illegitimacy under section 582(b)(4)(B)(ii)(II).

197

III. IDENTIFICATION OF SUSPECT PRODUCT AND, FOR MANUFACTURERS, PRODUCT WITH A HIGH RISK OF ILLEGITIMACY

198
199
200

201 As background, under section 582 of the FD&C Act, trading partners must have systems in place
202 that enable them, upon determining that a product in their possession or control is suspect or
203 upon receiving a request for verification from the FDA that has made a determination that a
204 product within the possession or control of the trading partner is a suspect product, to quarantine
205 suspect product and promptly conduct an investigation, in coordination with other trading
206 partners, as applicable, to determine whether a suspect product is illegitimate.

207

208 As trading partners conduct business on a daily basis, they should exercise vigilance, maintain
209 awareness about suspicious activity or potential threats to their supply chain, and devote
210 attention and effort to detect suspect product.

211

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

212 The next two sections of this guidance (A.) identify some specific scenarios that could
213 significantly increase the risk of suspect products entering the pharmaceutical distribution supply
214 chain and (B.) make recommendations to assist trading partners in identifying suspect product
215 and making determinations about whether a product is suspect as soon as practicable. The
216 scenarios contained in this guidance are based on Agency experience with suspect product in the
217 drug supply chain. These examples are illustrative and should be viewed as guidance rather than
218 as an exhaustive list of all potential scenarios that increase the likelihood that a suspect product
219 could enter the pharmaceutical distribution supply chain. Trading partners should consider the
220 surrounding circumstances of any particular scenario they may encounter in determining whether
221 or not a product is suspect, including whether multiple scenarios are present in any given
222 transaction.

223

224 **A. Specific Scenarios That Could Significantly Increase the Risk of a Suspect**
225 **Product Entering the Pharmaceutical Distribution Chain**

226

227 There may be situations involving trading partners where heightened vigilance would be
228 appropriate. In addition, there could be identifiable characteristics of products that might
229 increase the likelihood that they are suspect products. The following are examples of some
230 specific scenarios that could significantly increase the risk of a suspect product entering the drug
231 supply chain. Thus, trading partners should be particularly diligent when engaging in
232 transactions that involve:

233

234 *1. Trading Partners and Product Sourcing*

235

236 • Purchasing from a source new to the trading partner.

237

238 • Receiving an unsolicited sales offer from an unknown source. Trading partners
239 might receive unsolicited offers or advertisements through an email, a fax, a
240 telephone call, or an in-person sales call from a person or entity with whom they
241 do not have an established business relationship.

242

243 • Purchasing on the Internet from an unknown source. Trading partners might be
244 searching for a better price on the Internet or for a product that they cannot obtain
245 from their usual source, and might be tempted to turn to a person or entity with
246 whom they do not have an established business relationship.

247

248 • Purchasing from a source that a trading partner knows or has reason to believe has
249 engaged in questionable or suspicious business practices that could increase the
250 risk of suspect product entering the supply chain, such as:

251

252 - A trading partner that has been involved in business transactions where
253 they sold or delivered illegitimate product.

254

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

- 255 - A trading partner that has a history of problematic or potentially false
256 transaction histories or pedigrees, such as those that contain misspelled
257 words or incomplete information.
258
- 259 - A trading partner that is reluctant to provide a transaction history
260 associated with the product being purchased, or does not do so in a timely
261 manner.
262
- 263 - A trading partner that provides transaction information, a transaction
264 statement, and/or transaction history that appears to be incomplete or
265 suspicious.
266
- 267 2. *Supply, Demand, History, and Value of the Product*
268
- 269 • Product that is generally in high demand in the U.S. market.
270
 - 271 • Product that is in higher demand because of its potential or perceived relationship
272 to a public health or other emergency (e.g., antiviral drugs).
273
 - 274 • Product that has a high sales volume or price in the United States.
275
 - 276 • Product offered at a price that is “too good to be true.”
277
 - 278 • Product that has been previously or is currently being counterfeited or diverted
279 (e.g., HIV, antipsychotic, or cancer drugs).
280
 - 281 • Product that has been previously or is currently the subject of a drug shortage (see
282 a list of current drugs in shortage at
283 [http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/
284 default.htm](http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/default.htm) and
285 <http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm> for more
286 information).
287
 - 288 • Product that has been or is the subject of an illegitimate product notification under
289 the DSCSA or other alert or announcement related to drug quality.
290
- 291 • Product that has been or is the subject of an FDA counterfeit or cargo theft alert
292
293 (See
294 [http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/
295 counterfeitmedicine/default.htm](http://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/counterfeitmedicine/default.htm) and
296 <http://www.fda.gov/iceci/criminalinvestigations/ucm182888.htm> for more
297 information).

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

- 298 3. *Appearance of the Product*
299
300 • Appearance of a package or a container used for transport (e.g., case or tote) that
301 seems suspicious (e.g., it has a label that contains misspellings or appears
302 different from the standard label for that product in color, font, images, or
303 otherwise).
304
305 • Package that exhibits unusual or excessive adhesive residues.
306
307 • Package that contains foreign identification features (such as a different drug
308 identification number where a National Drug Code (NDC) number would be
309 expected).
310
311 • Package that is missing information, such as the lot number or other lot
312 identification, or the expiration date.
313
314 • Package that is missing security or anti-counterfeiting technologies normally
315 featured on the FDA-approved product that are easily visible to the eye, such as
316 holograms, color shifting inks, neckbands or watermarks.
317
318 • Finished dosage form that seems suspicious (e.g., it has a different shape or color
319 from the FDA-approved product, a different or unusual imprint, an unusual odor,
320 or there are signs of poor quality like chips or cracks in tablet coatings or smeared
321 or unclear ink imprints).
322
323 **B. Recommendations on How Trading Partners Might Identify Suspect Product**
324 **and Determine Whether the Product Is a Suspect Product as Soon as**
325 **Practicable**
326

327 The following are recommendations for trading partners on ways that they can expeditiously
328 identify suspect product and determine whether the product is suspect (and, after investigation,
329 whether it is illegitimate).. In general, trading partners should exercise due diligence when
330 conducting business and should confirm that all trading partners are authorized. Trading partners
331 should discuss with each other any observations, questions, or concerns they have related to the
332 status of a drug as a suspect product to aid them in determining whether the drug should be
333 considered a suspect product. Trading partners should also contact regulatory authorities, law
334 enforcement, the drug's manufacturer or other available resources to aid in that determination
335 when additional expertise is called for to make an accurate assessment of the status of a drug as a
336 suspect product. If a trading partner receives a product in a secured transport container or sealed
337 homogenous case, trading partners should examine the appearance of that container as
338 recommended below. If trading partners observe anything suspicious, they should take steps to
339 ascertain whether the product inside the transport container is suspect. Strategies to identify
340 suspect product include, but are not limited to, the following recommendations:
341

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

- 342 • Be alert for offers of product for sale at a very low price or one that is “too good
343 to be true.”
- 344
- 345 • Closely examine the package and the transport container (such as the case or
346 tote):
- 347 - To look for signs that it has been compromised (e.g., opened, broken seal,
348 damaged, repaired, or otherwise altered). If a trading partner receives a
349 product in a secured transport container or sealed homogenous case, trading
350 partners should examine the appearance of that container to see if anything
351 about that appearance seems suspicious, such as a shrink wrap that has
352 unexpected markings, or a seal that is broken, torn, or repaired.
- 353 - To see if the package or the transport container has changed since the last
354 shipment of the same product type was received for an unexplained reason
355 (e.g., a notification about the change from the manufacturer has not been
356 received).
- 357 - To see if product inserts are missing, do not correspond to the product, or are
358 suspicious in some way.
- 359 - For shipping addresses, postmarks, or other materials indicating that the
360 product came from an unexpected foreign entity or source.
- 361
- 362 • Closely examine the label on the package, and the label on the individual retail
363 unit, if applicable, for:
- 364 - Any missing information, such as the lot number or other lot identification,
365 NDC, or strength of the drug.
- 366 - Any altered product information, such as smudged print or print that is very
367 difficult to read.
- 368 - Misspelled words.
- 369 - Bubbling in the surface of a label.
- 370 - Lack of an “Rx only” symbol⁶
- 371 - Foreign language with little or no English provided.⁷
- 372 - Foreign language that is used to describe the lot number.⁸
- 373 - A product name that differs from the name that appears on the FDA-approved
374 drug label or labeling.
- 375 - A product name that is the product name for a foreign version of the drug.
- 376 - A product that is transported in a case or tote, when not expected under the
377 circumstances.
- 378 - Lot numbers and expiration dates on product that do not match the lot
379 numbers and expiration dates of its outer container.

18 ⁶ Or, for products distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant
19 language is Spanish, “Solamente Rx”. 21 CFR 201.16

20 ⁷ Except for products distributed solely in the Commonwealth of Puerto Rico or in a Territory where the
21 predominant language is one other than English. 21 CFR 201.15 (c)(1)

22 ⁸ Except for products distributed solely in the Commonwealth of Puerto Rico or in a Territory where the
23 predominant language is one other than English. *Id.*

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

380
381 Again, under section 582 of the FD&C Act, trading partners must have systems in place that
382 enable them, upon determining that a product in their possession or control is suspect or upon
383 receiving a request for verification from the FDA that has made a determination that a product
384 within the possession or control of the trading partner is a suspect product, to quarantine suspect
385 product and promptly conduct an investigation, in coordination with other trading partners, as
386 applicable, to determine whether a suspect product is illegitimate. In addition, trading partners
387 must, as applicable, make the notifications described in sections 582(b)(4)(B)(ii)(I), (c)(4)(B)(ii),
388 (d)(4)(B)(ii), and (e)(4)(B) of the FD&C Act related to illegitimate product determinations, and,
389 for manufacturers, the notification of a high risk of illegitimacy described in section 582(b)(4)(B)
390 (ii)(II).

C. For Manufacturers: High Risk of Illegitimacy Notifications⁹

391
392
393
394 Section 582(b)(4)(B)(ii)(II) of the FD&C Act requires manufacturers to make notifications in
395 certain circumstances for products that pose a high risk of illegitimacy. The provision states as
396 follows:
397

398
399 *(II) HIGH RISK OF ILLEGITIMACY.--A manufacturer shall notify the Secretary*
400 *and immediate trading partners that the manufacturer has reason to believe may*
401 *have in the trading partner's possession a product manufactured by, or purported*
402 *to be a product manufactured by, the manufacturer not later than 24 hours after*
403 *determining or being notified by the Secretary or a trading partner that there is a*
404 *high risk that such product is an illegitimate product. For purposes of this*
405 *subclause, a 'high risk' may include a specific high risk that could increase the*
406 *likelihood that illegitimate product will enter the pharmaceutical distribution*
407 *supply chain and other high risks as determined by the Secretary in guidance*
408 *pursuant to subsection (h).*
409

410 FDA interprets this provision to require manufacturers to notify [1] FDA and [2] the
411 manufacturer's immediate trading partners (that the manufacturer has reason to believe may have
412 in the trading partner's possession a product manufactured by, or purported to be a product
413 manufactured by, the manufacturer) in three general scenarios:
414

- 415 1. Within 24 hours after determining or being notified by FDA or a trading partner that
416 there is a high risk that a product that the manufacturer has reason to believe is in an
417 immediate trading partner's possession is an illegitimate product.
- 418 2. Within 24 hours after determining or being notified by FDA or a trading partner that
419 there is a specific high risk that could increase the likelihood that illegitimate product
420 will enter the U.S. pharmaceutical distribution supply chain.

24 ⁹ This section of the guidance is being distributed for comment purposes only.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

421 3. Within 24 hours after determining or being notified by FDA or a trading partner that
422 there exists an “other high risk” as determined by FDA in guidance pursuant to
423 subsection 582(h).
424

425 FDA believes that Congress intended section 582(b)(4)(B)(ii)(II) to leverage the surveillance
426 systems that many manufacturers already have in place to detect counterfeit and otherwise
427 violative versions of their products. Manufacturers could learn about products with a high risk of
428 illegitimacy from a variety of sources, including from within their own company, from their
429 trading partners, from the FDA, or from other domestic and/or foreign regulatory authorities—
430 even when a product may not be in the manufacturer’s possession or control.
431

432 Below are scenarios and examples in which a manufacturer should make a notification under
433 section 582(b)(4)(B)(ii)(II).
434

1. High Risk of Illegitimacy Notification for Products that the Manufacturer Has Reason to Believe Are in an Immediate Trading Partner’s Possession

437
438 The first general scenario, described above, involves notifications for products that the
439 manufacturer has reason to believe are in an immediate trading partner’s possession.
440

441 An example of this scenario might occur when the manufacturer is asked to coordinate a suspect
442 product investigation by an immediate trading partner under section 582(c)(4)(B), 582(d)(4)(B),
443 or 582(e)(4)(B), and the manufacturer determines that there is a high risk that the product is
444 illegitimate. Some sample scenarios involving high risks of illegitimacy, where a manufacturer
445 should make a notification, include:
446

- 447 • A manufacturer learns from a trading partner that a suspect product purporting to be one
448 produced by that manufacturer has been found in the U.S. pharmaceutical distribution
449 supply chain. The manufacturer examines the suspect product and believes the product
450 could be illegitimate but wants to take additional steps before determining that it is
451 illegitimate. The manufacturer has reason to believe that additional illegitimate products
452 are in the possession of immediate trading partners. For example, a wholesale distributor
453 informs a manufacturer that it believes it has a counterfeit of that manufacturer’s product.
454 The wholesale distributor sends the product to the manufacturer. The manufacturer
455 examines the product and believes it could be counterfeit, but wants to perform a
456 laboratory or other analysis for confirmation.
457
- 458 • A manufacturer learns that its product has been stolen or diverted in the U.S. while not in
459 its possession or control, and the manufacturer has reason to believe that an immediate
460 trading partner might have the stolen or diverted product in its possession.
461

2. Specific High Risks That Could Increase the Likelihood of an Illegitimate Product Entering the U.S. Pharmaceutical Distribution Supply Chain

462
463
464

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

465 Section 582(b)(4)(B)(ii)(II) states that a high risk of illegitimacy may include a “specific high
466 risk” that could increase the likelihood that illegitimate product will enter the pharmaceutical
467 distribution supply chain. In such cases, the product has not yet entered the pharmaceutical
468 distribution supply chain, so no immediate trading partners would have it in their possession.
469 Section 582(b)(4)(B)(ii)(II) thus would require the manufacturer to make a notification to FDA,
470 but the manufacturer would not be required to notify immediate trading partners. To help ensure
471 the integrity of the supply chain, however, FDA recommends that a manufacturer notify its
472 immediate trading partners of such “specific high risk[s]” even if that manufacturer does not
473 have reason to believe that its immediate trading partners may have the high risk product in their
474 possession. Some factual examples involving specific high risks include:

- 475
476 • A manufacturer learns that a product with a high risk of illegitimacy (purporting to be
477 one produced by that manufacturer) has been found in another country, and that such
478 product is likely destined for a trading partner in the U.S. For example, the manufacturer
479 learns from a foreign regulatory authority that one of its products has been counterfeited
480 in another country, and that some of that product is on a cargo ship destined for the U.S.
481 for delivery to a wholesale distributor.
- 482
483 • A manufacturer learns that its product was stolen or diverted in another country, and that
484 such product is destined for the U.S. in a manner that leads the manufacturer to believe
485 the product will likely enter the U.S. pharmaceutical distribution supply chain. For
486 example, the manufacturer learns from a foreign law enforcement agency that its product
487 was stolen during transport in another country and is on a plane destined for the U.S. for
488 delivery to a dispenser.
- 489
490 • A manufacturer learns that there is a high risk that its product has been intentionally
491 adulterated in another country such that the product would result in serious adverse health
492 consequences or death to humans, and that such product is likely destined for the U.S. in
493 a manner that leads the manufacturer to believe the product will enter the pharmaceutical
494 distribution supply chain. For example, the manufacturer learns from its own
495 investigation that there is a high risk that a contaminant that would result in serious
496 adverse health consequences or death to humans was added to a product in another
497 country and sent to a repackager in the U.S.

498
499 As noted above, these examples in sections 1 and 2 are examples, rather than an exhaustive list
500 of circumstances in which trading partners should make notifications under section 582(b)(4)(B)
501 (ii)(II).

502 503 *3. Other High Risks as Determined by FDA: High Risk of Illegitimacy Notification Where* 504 *a Manufacturer has Reason to Believe the Product has Entered the Pharmaceutical* 505 *Distribution Supply Chain* 506

507 Section 582(b)(4)(B)(ii)(II) of the FD&C Act permits FDA to determine, through guidance
508 pursuant to section 582(h), “other high risks” that would trigger a notification under this

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

509 provision. FDA believes that one “other high risk” not covered by the two general scenarios
510 described above is when a manufacturer has reason to believe that an illegitimate product has
511 entered the pharmaceutical distribution supply chain, even though the manufacturer does not
512 have reason to believe that an immediate trading partner possesses the high risk product.¹⁰ As
513 with the second general scenario, described above, section 582(b)(4)(B)(ii)(II) would require the
514 manufacturer to make a notification to FDA, but the manufacturer would not be required to
515 notify immediate trading partners. To help ensure the integrity of the supply chain, however,
516 FDA recommends that a manufacturer notify its immediate trading partners of this “other high
517 risk,” even if that manufacturer does not have reason to believe that its immediate trading
518 partners may have the high risk product in their possession.

519 A manufacturer could learn that a product with a high risk of illegitimacy that was manufactured
520 by or purported to be manufactured by that manufacturer may be in the possession of a trading
521 partner, but that trading partner is not an immediate trading partner of the manufacturer. Some
522 examples which involve this other high risk:

- 523 • A manufacturer learns that a licensed health care practitioner is administering an
524 oncology drug to patients that purports to have been manufactured by that manufacturer
525 but the manufacturer determines that there is a high risk that the drug is a counterfeit. The
526 licensed health care practitioner purchased the drug from a wholesale distributor, so
527 he/she is not an immediate trading partner of the manufacturer. However, the
528 manufacturer believes that the product has entered the pharmaceutical distribution supply
529 chain.
- 530 • A manufacturer learns that its product has been stolen or diverted in the U.S., and the
531 manufacturer learns that a patient filled a prescription and received some of the stolen or
532 diverted product. The patient suffers an adverse event and FDA and the manufacturer is
533 notified of that situation. Because the dispenser did not purchase the product from the
534 manufacturer, it is not an immediate trading partner of the manufacturer. However, the
535 product has entered the pharmaceutical distribution supply chain.
- 536 • A manufacturer learns that wholesale distributor B received product and transaction
537 history going back to the manufacturer from wholesale distributor A, but the listed
538 dosage form of the product on the transaction history is not one that has ever been used
539 by the manufacturer. Wholesale distributor B provided a copy of the transaction history
540 it received from wholesale distributor A to the manufacturer, and the manufacturer
541 concluded after reviewing the copy and receiving similar reports from other trading
542 partners that a fraudulent transaction had occurred. Because wholesale distributor B did
543 not purchase the product from the manufacturer, it is not an immediate trading partner of
544 the manufacturer. However, the product has entered the pharmaceutical distribution
545 supply chain.

25 ¹⁰ FDA reserves authority to articulate additional “other high risk[s]” in subsequent guidance.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587

IV. NOTIFICATION OF ILLEGITIMATE PRODUCT AND PRODUCTS WITH A HIGH RISK OF ILLEGITIMACY

A. Notification to FDA

As discussed above, trading partners must, as applicable, make the notifications described in sections 582(b)(4)(B)(ii)(I), (c)(4)(B)(ii), (d)(4)(B)(ii), and (e)(4)(B)(ii) of the FD&C Act related to illegitimate product determinations, and, for manufacturers, the notification of a high risk of illegitimacy described in section 582(b)(4)(B)(ii)(II). This section of the guidance addresses the process by which trading partners should notify FDA and trading partners regarding illegitimate products under section 582. After review of the circumstances surrounding the event, if FDA determines that notification is not required under either section 582(b)(4)(B)(ii)(I), (c)(4)(B)(ii), (d)(4)(B)(ii), (e)(4)(B)(ii) or (b)(4)(B)(ii)(II) of the FD&C Act, FDA intends to inform the submitting entity.

1. The following process should be used to notify FDA of illegitimate products:

- (1) Trading partners should access FDA’s Web page at <http://www.accessdata.fda.gov/scripts/cder/email/drugnotification.cfm> for notifications.
- (2) Trading partners should follow the instructions on the Web page for accessing Form FDA 3911 (Attachment A). Using this form, trading partners should provide information about the person or entity initiating the notification, the product determined to be illegitimate that is the subject of the notification to FDA, and a description of the circumstances surrounding the event that prompted the notification.
- (3) Form FDA 3911 should be submitted using the method provided in the form or on the Web page.
- (4) FDA will acknowledge receipt of the notification and assign an incident number. This number should be referenced in all future correspondence about the illegitimate product including any request for termination.
- (5) In addition to notifying FDA, the trading partner that determines that it has an illegitimate product in its possession or control must notify all immediate trading partners that it has reason to believe may also possess the drug. Trading partners may notify other trading partners of an illegitimate product using existing systems and processes used for similar types of communications to those partners, which might include, but are not limited to, posting of notifications on a company Web site, telephoning, sending an email, or mailing or faxing a notification.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

588 2. *The following process should be used by manufacturers to notify FDA of a product*
589 *with a high risk of illegitimacy:*

- 590
- 591 (1) To notify FDA of a product with a high risk of illegitimacy under section 582(b)(4)(B)
592 (ii)(II), manufacturers should follow the instructions on the Web page for accessing
593 Form FDA 3911 (Attachment A). Using this form, manufacturers should provide
594 information about the person or entity initiating the notification, the product determined
595 to have a high risk of illegitimacy that is the subject of the notification to FDA, and a
596 description of the circumstances surrounding the event that prompted the notification.
597
- 598 (2) FDA will acknowledge receipt of the notification and assign an incident number. This
599 number should be documented in all future correspondence about the product with the
600 high risk of illegitimacy including the request for termination.
601
- 602 (3) In addition to notifying FDA, the manufacturer that determines that a product has a high
603 risk of illegitimacy must notify all immediate trading partners that it believes may
604 possess the drug. Manufacturers may notify trading partners of a product with a high
605 risk of illegitimacy using existing systems and processes used for similar types of
606 communications to those partners, which might include, but are not limited to, posting of
607 notifications on a company Web site, telephoning, sending an email, or mailing or
608 faxing a notification.
609
- 610 (4) If a product with a high risk of illegitimacy is found to be an illegitimate product,
611 manufacturers should submit a follow-up notification that explains the updated
612 classification and references the incident number of the original notification of high risk
613 of illegitimacy.
614
- 615 (5) If it is determined that a product that was subject to a high risk of illegitimacy
616 notification is not an illegitimate product, manufacturers must submit a request for
617 termination of the high risk of illegitimacy notification to the FDA according to the
618 process in Section B below.
619

B. Termination of Notification in Consultation With FDA¹¹

620

621

622 Section 582(h)(2)(A) of the FD&C Act directs FDA to issue guidance setting forth the process
623 that trading partners shall follow for terminating notifications regarding illegitimate product, or
624 for manufacturers, terminating notification of a high risk of illegitimacy, in consultation with
625 FDA, under section 582(b)(4)(B), (c)(4)(B), (d)(4)(B), and (e)(4)(B). Section 582(b)(4)(B), (c)
626 (4)(B), (d)(4)(B), and (e)(4)(B) require trading partners to have in place systems to enable them
627 to terminate notifications, in consultation with FDA, when appropriate. This section of the
628 guidance addresses the process by which trading partners must terminate such notifications in
629 consultation with FDA. This process must be used when trading partners believe that a
630 notification they made to FDA regarding illegitimate product, or for a manufacturer, a

26 ¹¹ As described above, this section of the guidance document is binding.

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

631 notification of a high risk of illegitimacy, is no longer necessary.

633 The process for terminating notifications in consultation with FDA is as follows:

634

635 (1) The trading partner making a notification to the FDA shall be responsible for making the
636 request for termination.

637

638 (2) Trading partners must access FDA's Web page at
639 <http://www.accessdata.fda.gov/scripts/cder/email/drugnotification.cfm> for termination of
640 notifications.

641

642 (3) Trading partners must follow the instructions on the Web page for accessing Form FDA
643 3911 (Attachment A). Using this form, trading partners must provide to FDA
644 information about the person or entity initiating the request for termination, the
645 illegitimate product or the product with a high risk of illegitimacy, the notification that
646 was issued, and an explanation about what actions have taken place or what information
647 has become available that make the notification no longer necessary. Trading partners
648 should include the FDA-assigned incident number associated with the notification on the
649 request for termination.

650

651 (4) This form must be submitted by using the method provided in the form or on the Web
652 page. The trading partner's submission of a request for termination of a notification will
653 be viewed as a request for consultation with FDA, as required in section 582 of the
654 FD&C Act. FDA may request additional information it determines necessary to
655 complete the consultation.

656

657 (5) FDA will review the request and consult with the trading partner. The response time will
658 depend on the number of requests for termination and the circumstances surrounding the
659 requests for termination that are received by FDA.

660

661 FDA interprets the DSCSA's requirement for trading partners to "mak[e] a determination, in
662 consultation with the Secretary, that a notification is no longer necessary"¹² to require that
663 trading partners provide the Agency with an opportunity to provide its expert views and advice
664 on proposed terminations of notifications. Therefore, a trading partner must wait until FDA
665 responds to the termination request before the trading partner notifies other trading partners that
666 a notification is terminated. FDA intends to respond to requests for termination within 10
667 business days of submission. In some cases, FDA may contact a trading partner to notify the
668 partner that additional time is needed to respond to the request for termination. If a trading
669 partner believes that exigent circumstances require expedited consideration of a termination
670 request (e.g., a potential drug shortage), the trading partner must describe those circumstances in
671 the termination request to FDA on the FDA Form 3911 when making the request for termination.

672

27 ¹² FD&C Act § 582(b)(4)(iv), (c)(4)(B)(iv), (d)(4)(B)(iv), and (e)(4)(B)(iv).

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

Contains Nonbinding Recommendations*

673 Under section 582(b)(4)(B), (c)(4)(B), (d)(4)(B), and (e)(4)(B) of the FD&C Act, after FDA
674 provides its consultation response, and the trading partner determines that the notification is no
675 longer necessary, the trading partner that made the request for termination must promptly notify
676 immediate trading partners that the notification has been terminated. Trading partners may
677 notify their trading partners of a termination using existing systems and processes used for
678 similar types of communications to those partners, which might include, but are not limited to,
679 posting of notifications on a company Web site, telephoning, sending an email, or mailing or
680 faxing a letter or notification.
681

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product and products with a high risk of illegitimacy in consultation with FDA, it has binding effect.

*Contains Nonbinding Recommendations**

682
683

ATTACHMENT A: FORM FDA 3911

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.

Contains Nonbinding Recommendations*

DRAFT

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Drug Notification	Form Approved: OMB No. xxxx-xxxx Expiration Date: XXXXXXX xx, 201x See PRA Statement on page 2.
---	---

Refer to instruction sheet (Form FDA 3911 Supplement) for more information.

1. Type of Report (Select one): Initial Notification Follow-Up Notification Request for Termination

2. Incident Number (Provide this number, assigned by FDA, if you selected Follow-up Notification or Request for Termination above; see instructions.)

3. Date of Initial Notification (mm/dd/yyyy)	4. Date Company Determined Product Was Illegitimate (mm/dd/yyyy)	5. Classification of Notification (Select from list)

Description of Product

6. Name of Product as It Appears on Label

7. Primary Ingredients(s) (if known)

8. Drug Use (Select from list)	9. Drug Description (Select from list)

10. Strength of Drug	11. Dosage Form (Select from list)

12. Quantity of Drug (Number and Unit)	13. NDC Number (if applicable)	14. Serial Number (if applicable)

15. Lot Number(s)

16. Expiration Date(s)

17. For Notification: Description of Event/Issue

Add Page for Item 17

18. For Request for Termination of Notification: Description of why notification is no longer necessary

Add Page for Item 18

19. If you have submitted information to FDA through an alternative mechanism, check all that apply.

BPDR MedWatch 3500 None
 FAR MedWatch 3500A Other (Specify): _____

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.

Contains Nonbinding Recommendations*

DRAFT

Company/Facility Information

20. Company Name & Address

Name	
Address 1 (Street address, P.O. box, etc.)	
Address 2 (Apartment, suite, unit, building, floor, etc.)	
City	State/Province/Region
Country	ZIP or Postal Code

21. Company Category (Select from list)

22. Unique Facility Identifier (of company named in #20)

23. Contact Information (Note: For the telephone, you may enter the number of either the contact person or of the company named in #20.)

Name	Telephone Number (Include area code)
Email Address	

SUBMIT BY EMAIL

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 1 hour per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

685
686
687

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.

Contains Nonbinding Recommendations*

INSTRUCTIONS FOR COMPLETION OF FORM FDA 3911 – DRUG NOTIFICATION

(The item numbers below correspond to the numbered areas on Form FDA 3911)

1. Type of Report – Indicate the type of report by checking the appropriate box.

- Initial Notification – Your first notification to the FDA of an illegitimate product or product with a high risk of illegitimacy
- Follow-up Notification – subsequent notification to FDA, related to an initial notification already submitted to FDA
- Request for Termination – request for consultation with FDA to terminate a notification of an illegitimate product or product with a high risk of illegitimacy

2. Incident Number – This number will be assigned by FDA when the initial notification is received by FDA and sent to the reporter with the FDA receipt acknowledging the initial notification. Please utilize the incident number that corresponds to the initial notification in all future correspondence with the FDA about the notification, including the request for termination.

3. Date of Initial Notification – Enter the date that you are submitting the initial notification. For follow-up notifications or a request for termination, enter the date the initial notification was submitted to FDA. Use the calendar function or enter the date in MM/DD/YYYY format. If you do not have the incident number, then providing the date of initial notification will allow FDA to associate any follow-up notification or request for termination with the initial notification.

4. Date Illegitimate Product Was Determined by Company – Use the calendar function or enter the date in MM/DD/YYYY format that the product was determined to be illegitimate or to have a high risk of illegitimacy (manufacturers only).

5. Classification of Notification – Select the appropriate classification of the illegitimate product or product with a high risk of illegitimacy (manufacturers only).

- Counterfeit – A product is determined to be counterfeit, or has a high risk of being counterfeit.
- Diverted – A product is determined to be a diverted product, or has a high risk of being a diverted product.
- Stolen – A product is determined to be a stolen product, or has a high risk of being a stolen product.
- Intentional adulteration – A product is determined to be intentionally adulterated such that use of the product would result in serious adverse health consequences or death to humans, or has a high risk of it.
- Unfit for distribution – A product appears otherwise unfit for distribution such that use of the product would be reasonably likely to result in serious adverse health consequences or death to humans, or has a high risk of it.
- Fraudulent transaction – A product in your possession or control is determined to be the subject of a fraudulent transaction, or has a high risk of it.

Description of Product

6. Name of Product as it appears on the label– Indicate the name of the product as it appears on the label.

7. Primary Ingredient(s) – List active pharmaceutical or biological ingredient(s) if known and not listed in item 6 above.

8. Drug Use – Select the approved use of the product. If “other” is selected, please provide a description in your response to item 17 or 18. Note: Section 582 of the FD&C Act notifications are for human-use products only

- Human use
- Other

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.

Contains Nonbinding Recommendations*

9. Drug Description – Select the most specific description available from the list that describes the illegitimate product or product with high risk of illegitimacy (manufacturers only).

- Finished prescription drug
- Vaccine
- Plasma derivative (coagulation factors, immunoglobulins, albumin)
- Allergenic (standardized and non-standardized)

10. Strength of Drug – Provide the strength of the product, including the unit of measure (e.g., 500 mg, 1g/10mL).

11. Dosage Form – Select the dosage form that best describes the product. If “OTHER” is selected, provide a description in your response to item 17 or item 18.

- Tablet
- Capsule
- Aerosol
- Oral Liquid
- Sublingual
- Injectable
- Topical
- Suppository
- Other

12. Quantity of Drug (Number and Unit) – Provide the quantity of product involved, including the number and unit of measure (e.g., 6 cases, 20 bottles, etc.). Additional information may be included in item 17 or item 18.

13. NDC Number – Provide the National Drug Code of the product as identified on the product that is subject to the notification if known.

14. Serial Number – Provide the serial number as identified on the product that is subject to the notification if known.

15. Lot Number(s) – Provide any relevant lot numbers of the product that is subject to the notification if known. Separate multiple numbers using a comma.

16. Expiration Date(s) – Provide expiration date(s) as identified on the product that is subject to the notification if known. Separate multiple expiration dates using a comma.

17. For Notification, Description of Event/Issue – Describe the circumstances surrounding the event that prompted the notification including, when, where in the supply chain, where geographically, and how the product was found. If you are a trading partner other than a manufacturer, you may indicate which manufacturer you have coordinated with to make the determination that the product is illegitimate here. If this notification is for a product with a high risk of illegitimacy (manufacturers only), indicate it here.

18. For Request for Termination of Notification: Description of why notification is no longer necessary – Explain why the notification is no longer needed including any corrective actions taken, if applicable. If expedited consultation with FDA is requested, please indicate the rationale here.

19. If you have also submitted the information to FDA through an alternative mechanism, check all other voluntary or required reporting that apply. Identify any voluntary or required reporting that the company has sent to FDA for the related event/issue that prompted the notification. If “OTHER” is selected,

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.

Contains Nonbinding Recommendations*

include a short description in the blank space provided. If the specific case number(s) is known, please indicate the number(s) in the response in item 17 or item 18.

- FAR- Field Alert Report
- BPDR - Biological Product Deviation Report
- Medwatch 3500
- Medwatch 3500A
- None
- Other

Company/Facility Information

20. Company Name & Address – Provide the following information for the company responsible for making the notification.

- Company Name – Provide the name of the company that is responsible for making the notification.
- Address – In Address 1, provide the mailing address including number and street name; and (if applicable) in Address 2 provide room, suite, or department.
- City – Self explanatory.
- State/Province/Region – Self explanatory. *(If U.S., use approved postal two letter abbreviation.)*
- Country – Self explanatory.
- ZIP/Postal Code – Self explanatory. *(If U.S., provide 5 or 9 digit ZIP code.)*

21. Company Category – Select the appropriate category that describes the company responsible for making the notification (listed in item 20).

- Manufacturer
- Wholesale distributor
- Dispenser (Pharmacy)
- Repackager

22. Unique Facility Identifier – Provide the unique identifier for the company making the notification. The Unique Facility Identifier should be a D-U-N-S Number for the location of the company named in item 20. If the company has not obtained a D-U-N-S number for the relevant location at the time it submits this form, this field should be left blank. For a facility that has not been assigned a number, a number may be obtained for no cost directly from Dun & Bradstreet (<http://www.dnb.com>).

23. Contact Information – Provide the following contact information for a person at the company identified in item 20. FDA may use this information to contact a responsible person for follow-up information about the notification.

- Name of Contact Person – Self explanatory.
- Telephone Number – Provide the telephone number and extension of the contact person or of the company listed in item 20.
- Email Address of Contact Person – Self explanatory

* Insofar as section IV.B of this guidance sets forth the process by which trading partners must terminate notifications of illegitimate product in consultation with FDA, it will have binding effect upon finalization.